Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases

Inflammatory Bowel Disease

Treatment of Inflammatory Bowel Disease in the Older Patient

Inflamm Bowel Dis.

Dorreen A, Heisler C, Jones J

doi: 10.1093/ibd/izy023.

Inflammatory Bowel Disease

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Eur J Gastroenterol Hepatol.

Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complication

Clin Gastroenterol Hepatol.

Siegel CA, Bernstein CN

doi: 10.1016/j.cgh.2019.11.034.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study

doi: 10.1093/ecco-jcc/jjy183.

Inflammatory Bowel Disease

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Inflamm Bowel Dis.

Lin SC, Goldowsky A, Papamichael K, Cheifetz AS

doi: 10.1093/ibd/izy376.

Inflammatory Bowel Disease

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial

Inflamm Bowel Dis.

Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A

doi: 10.1097/

Inflammatory Bowel Disease

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Eur J Gastroenterol Hepatol.

Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study

doi: 10.1097/

RECOMMENDED

Inflammatory Bowel Disease

Preventive Medicine in Inflammatory Bowel Disease

Clin Gastroenterol Hepatol.

Weaver KN, Long MD

doi: 10.1016/j.cgh.2018.11.054.

Related content

Treatment of Inflammatory Bowel Disease in the Older Patient

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complication

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Preventive Medicine in Inflammatory Bowel Disease